Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA
Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions ( Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA )
19 Mar 2015

DNA repair inhibitors to overcome drug resistance

Dr Ruth Plummer - Newcastle University, Newcastle, UK
DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )
11 Mar 2015

Refining the role of PARP inhibitors in targeted anticancer therapy

Prof Yves Pommier - National Cancer Institute, Bethesda, USA
Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier - National Cancer Institute, Bethesda, USA )
11 Mar 2015

Developments in immunotherapy

Prof Lillian Siu - University Health Network, Toronto, Canada
Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )
11 Mar 2015

Radiogenomic evaluation of tumour response to targeted agents

Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA
Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )
10 Mar 2015

Drugging the cancer genome to overcome drug resistance

Prof Paul Workman - Institute of Cancer Research, UK
Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )
10 Mar 2015

ecancermedicalscience editor's choice for February 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
3 Mar 2015

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )
28 Feb 2015

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Dr Joaquin Mateo - Institute of Cancer Research, London, UK
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )
27 Feb 2015

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer

Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA
Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer ( Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA )
27 Feb 2015

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
11 Feb 2015

mRCC: Are we doing all we can to manage adverse events?

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
11 Feb 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation